Cohort A (n = 218) | Cohort B (n = 26) | Cohort C (n = 111) | Overall (n = 355) | |
---|---|---|---|---|
Median age, years | 64 | 61 | 61 | 63 |
Family history, breast/ovarian cancer, n (%) | 35 (16) | 3 (12) | 29 (26) | 67 (19) |
ECOG performance status, n (%) | ||||
0–1 | 168 (77) | 26 (100) | 94 (85) | 288 (81) |
2–4 | 44 (20) | 0 | 17 (15) | 61 (17) |
Missing | 6 (3) | 0 | 0 | 6 (2) |
AJCC stage grouping, n (%) | ||||
IIIA | 41 (19) | 4 (15) | 16 (14) | 61 (17) |
IV | 146 (67) | 22 (85) | 70 (63) | 238 (67) |
PgR-positive status, n (%)a | 155 (71) | 19 (73) | 69 (62) | 243 (68) |
Tumor proliferation, n (%)a | ||||
Ki-67 status <20 % | 26 (12) | 2 (8) | 20 (18) | 48 (14) |
Grade 3 | 100 (46) | 11 (42) | 53 (48) | 164 (46) |
Metastatic site, n (%) | ||||
Brain | 6 (3) | 0 | 13 (12) | 19 (5) |
Lung | 72 (33) | 6 (23) | 36 (32) | 114 (32) |
Liver | 61 (28) | 3 (12) | 52 (47) | 116 (33) |
Bone | 118 (54) | 22 (85) | 60 (54) | 200 (56) |